Natco Pharma, operating in the Pharmaceuticals sector and classified as a Smallcap on the BSE, currently has its share price at ₹826.85. The stock has experienced fluctuations today, with a low ...

As it expands its business across new therapeutic areas such as Hepatitis C and cardio-diabetology, the Street believes Natco is well-placed to counter macro headwinds facing the pharma sector.

Learn about Natco Pharma Ltd. in Hyderabad, Telangana.Find comprehensive contact details, including phone numbers and email addresses, and get directions to the location. If you own or are ...

Natco Pharma on April 8 said that the launch of its generic version of Roche Pharma's patented drug, Risdiplam, is contingent upon the successful outcome in a patent infringement case.

A two-judge bench of Delhi High Court on Wednesday refrained Natco Pharma from launching the generic version of Swiss drugmaker Roche Pharma's patented drug Risdiplam until the hearing on April 2.

Natco Pharma on Tuesday shared a legal update on the legal proceedings on the Risdiplam compound (used for treating spinal muscular atrophy) launch in India. "The company has received numerous ...

Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900. In an update on the legal proceedings on the ...

Natco Pharma Q3 Results: NATCO Pharma Ltd reported a sharp decline of 37.75 percent in consolidated net profit for the December quarter, primarily impacted by a downturn in formulations exports.

Drugmaker Natco Pharma on Tuesday said it intends to launch its generic version of spinal muscular atrophy drug Risdiplam only after and subject to successful clarity from the Appellate Bench of ...